阿法替尼治疗HER2突变非小细胞肺癌:欧洲胸科肿瘤平台(ETOP)前瞻性开放标签II期NICHE试验结果
NICHE是一项单臂II期试验,采用两阶段Simon设计,评估阿法替尼40mg/天治疗既往治疗过的HER2外显子20突变晚期NSCLC。共入组13例,7例(53.8%)在12周时达到疾病控制;中位无进展生存期15.9周(95%CI 6.0-35.4),中位总生存期56.0周(95%CI 16.3-上限不可估计)。结论认为阿法替尼未显示出预期的疾病控制潜力。
要点
- 13例HER2外显子20突变晚期NSCLC患者接受阿法替尼40mg/天治疗。
- 12周疾病控制率为53.8%(7/13),中位PFS为15.9周。
- 中位OS为56.0周,毒性谱在预期范围内。
核心结论
- 阿法替尼在HER2突变NSCLC中未显示出预期的疾病控制潜力,但全队列中超过半数患者在12周时达到疾病控制。
研究设计与样本
- NICHE是一项单臂II期试验,采用两阶段Simon设计,评估阿法替尼对既往治疗过的HER2外显子20突变晚期NSCLC患者的疾病控制潜力。
- 共13例患者入组,接受阿法替尼40mg/天治疗,直至肿瘤进展或无法耐受。
主要发现
- 9例患者中有5例未在12周时达到疾病控制,因而跨越了第一阶段停止边界,试验入组在共13例患者时停止。
- 13例患者中7例(53.8%)在12周时达到疾病控制。
- 除1例早期死亡外,所有患者均记录到疾病进展,中位无进展生存期为15.9周(95%CI 6.0-35.4),中位总生存期为56.0周(95%CI 16.3-上限不可估计)。
- 毒性谱在预期范围内。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Mutations in erb-b2 receptor tyrosine kinase 2 (HER2) oncogene are observed in approximately 3% of lung adenocarcinomas or mixed tumors with adenocarcinoma component. Activity of various biologically distinct HER2 inhibitors, including the pan-HER inhibitor afatinib, has been reported in several retrospective trials or small series in advanced pretreated NSCLC with HER2 mutations. We report the first prospective evaluation of afatinib for the treatment of this molecularly defined entity. METHODS: NICHE, a single-arm phase II trial using a two-stage Simon's design, explored the potential of afatinib to control disease in pretreated patients with advanced NSCLC harboring HER2 exon 20 mutations. A total of 13 patients entered the trial and were treated with afatinib 40 mg/day until tumor progression or lack of tolerability. RESULTS: The first-stage stopping boundary was crossed when five of nine patients did not achieve disease control at 12 weeks. The accrual into the trial was stopped with total 13 patients enrolled, with 7 (53.8%) achieving disease control at 12 weeks. Except for 1 patient with early death, progression was documented for all patients, with median progression-free survival of 15.9 weeks (95% confidence interval: 6.0-35.4), and median overall survival of 56.0 weeks (95% confidence interval: 16.3- upper limit not estimable). The toxicity profile was in the expected range. CONCLUSIONS: Afatinib did not show the expected potential for disease control in NSCLC. However, more than half of the patients in the full cohort achieved disease control at 12 weeks.
引用
- Dziadziuszko R, Smit EF, Dafni U, et al. Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP). J Thorac Oncol. 2019. PMID: 30825613. doi:10.1016/j.jtho.2019.02.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。